1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

New Data Bolsters Cosentyx In AS & PsA; Humira Head-To-Head Planned

 
• By Sten Stovall

Novartis AG has unveiled fresh data supporting the efficacy of its Cosentyx (secukinumab) drug in ankylosing spondylitis and psoriatic arthritis along with plans to compare that front-running anti-IL-17A agent against AbbVie Inc.'s anti-TNF competitor Humira (adalimumab) in head-to-head clinical trials.

Vasant Narasimhan
Vasant Narasimhan • Source: Novartis AG

New long-term clinical data on Novartis' Cosentyx suggest that the first-in-class interleukin-17 inhibitor may lead to higher responses than Humira does in improving the signs and symptoms of people living with ankylosing spondylitis and psoriatic arthritis at 52 weeks, according to the Swiss company.

The data were contained in scientific abstracts presented by it at the annual European Congress of Rheumatology (EULAR 2016) in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Boehringer Scores First Approval For Targeted Oral Drug In HER2-Mutant NSCLC

 
• By Alaric DeArment

The US FDA approved Hernexeos for previously treated HER2-mutant NSCLC, making it the first oral option in a setting where drugs like AstraZeneca/Daiichi Sankyo’s Enhertu dominate.

Sjögren’s Success For Ianalumab Shores Up Novartis’s Pipeline-In-A-Product Plans

 
• By Alexandra Shimmings

Novartis has strengthened its argument that ianalumab, its BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate, has PIP potential with successful topline results in two Phase III Sjögren’s syndrome trials, after recently dropping the product in hidradenitis suppurativa.

Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win

 
• By Alaric DeArment

The FDA is expected to rule on the anti-CD20xCD3 bispecific combined with rituximab/lenalidomide in second-line follicular lymphoma in November.